In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma.

CRISPR-Cas9 genome engineering has increased the pace of discovery for immunology and cancer biology, revealing potential therapeutic targets and providing insight into mechanisms underlying resistance to immunotherapy. However, endogenous immune recognition of Cas9 has limited the applicability of CRISPR technologies in vivo. Here, we characterized immune responses against Cas9 and other expressed CRISPR vector components that cause antigen-specific tumor rejection in several mouse cancer models. To avoid unwanted immune recognition, we designed a lentiviral vector system that allowed selective CRISPR antigen removal (SCAR) from tumor cells. The SCAR system reversed immune-mediated rejection of CRISPR-modified tumor cells in vivo and enabled high-throughput genetic screens in previously intractable models. A pooled in vivo screen using SCAR in a CRISPR-antigen-sensitive renal cell carcinoma revealed resistance pathways associated with autophagy and major histocompatibility complex class I (MHC class I) expression. Thus, SCAR presents a resource that enables CRISPR-based studies of tumor-immune interactions and prevents unwanted immune recognition of genetically engineered cells, with implications for clinical applications.
Competing Interests: Declaration of interests This work was supported in part by funding from Calico Life Sciences. J.D., W.N.H., K.B.Y., and R.T.M. are authors of a patent application related to the SCAR vector system. R.T.M. consults for Bristol-Myers Squibb and Tango Therapeutics; W.N.H. is an employee of Merck & Co and has equity in Tango Therapeutics and ArsenalBio. H.W.P. is an employee of Arsenal Bio. I.C.K. is an employee of eGenesis Bio. J.G.D. consults for Foghorn Therapeutics, Maze Therapeutics, Merck & Co, Agios, and Pfizer and consults for and has equity in Tango Therapeutics.
(Copyright © 2021 Elsevier Inc. All rights reserved.)